Meetings

6th – 7th December 2023

EPO will attend the 12th Tumor Models London Summit, London, UK

The Tumor Models London Summit in December is an industry-led meeting dedicated to preclinical and translational oncology. This meeting will provide an update on newest tumor model developments, and their use in translating preclinical data into clinical applications. During the meeting EPO will be part of the dialogue between biopharma, research institutes and academia. 

EPO is proud to be listed as exhibition partner of the meeting.

11th to the 15th of October

EPO will attend the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics at the Hynes Convention Center in Boston from the 11th to the 15th of October

The 2023 Molecular Targets and Cancer Therapeutics conference, hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, will take place at Boston's Hynes Convention Center. The conference focuses on advancements in cancer drug development, target selection and early clinical trials.

We are very proud to announce that two of our abstracts have been accepted for poster presentation:

Poster 1: Patient-derived xenograft models from hematological malignancies for preclinical drug development and biomarker research (Abstract # 35592, Poster Session A)

Poster 2: Preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers in humanized mouse models (Abstract # 35527, Poster Session A)

Download: Poster 1 , Poster 2

11th-14th September 2023

EPO is presenting at the German Conference on Bioinformatics (GCB) from 11th to 14th of September 2023 in Hamburg, Germany

EPO is pleased to announce its active participation in the annual international GCB conference, held this year at the DESY accelerator centre in Hamburg, Germany. This conference is devoted to all areas of bioinformatics research. In the poster session, EPO presents its comprehensive HLA profile portfolio of 453 PDX models and its importance in enabling personalized, preclinical immune-oncology studies.

Poster #74: Human leukocyte antigen (HLA) typing of a broad panel of cancer patient-derived xenograft (PDX) models enables personalized, preclinical immune-oncology studies

Presenter: Dr. Theresia Conrad

Download poster

7th – 8th July 2023

EPO presents novel data on its HNSCC PDX models at the AACR-AHNS Head and Neck Cancer Congress in Montreal, QC, Canada

The American Association for Cancer Research (AACR) and the American Head and Neck Society (AHNS) host the third AACR-AHNS Joint Conference in Montreal, Canada, where EPO is also actively participating with a poster. This poster shows EPOs new data on its head and neck cancer PDX model panel regarding chemosensitivity testing, molecular characterization and HLA-matching analyses. We are happy to meet you at the poster to discuss our models and potential collaboration opportunities!

Poster: : New patient derived head and neck xenograft (PDX) for drug development, immune-oncology and translational research

  Download this poster (8th July 2023)

June 12th – 15th 2023

EPO will present current research topics at the Annual EACR Congress in Torino, Italy

The European Association of Cancer Research will have its Annual Meeting on Innovative Cancer Science in June 2023 in Torino, Italy. This meeting is covering a broad spectrum of preclinical and translational aspects of cancer research and EPO is proud to present its own newest research during this meeting. Our posters will provide interesting insights into our achievements with an excellent opportunity for scientific discussions.

• Poster # 1: Humanized mouse models for preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers (EACR23-0871; Section Tumour Biology)
  

Presenter:  Dr.-Ing. Maria Stecklum, who was awarded with the EACR Travel Grant

Download this poster (June 15th 2023)


---

• Poster # 2: Peritoneal metastasis of colorectal cancer (pmCRC): Identification of predictive molecular signatures by a novel preclinical platform of pmCRC PDX models (EACR23-1083; Section Translational Research)
  

Presenter:  Dr. Mathias Dahlmann

25th of May 2023

EPO is proud to invite to the EPO Spring Meeting in Berlin, Germany

EPO is pleased to announce the EPO Spring Meeting 2023 and to invite scientists from academia and industry to talk about novel developments in cancer models and to discuss future directions of research and collaborative activities. This Spring Meeting, which will take place in the historic Magnushaus, close to the Museum Island at the Spree River, right in the city center. The meeting covers different topics of cancer immunology, humanized mouse models, cancer biology, funding opportunities for collaboration of CROs and academia to expedit cancer research for novel therapies.

This symposium offers great opportunities for scientific exchange and discussions and the detailed program can be found here. Please register as soon as possible by writing an email to Katja Bolle (Turn on Javascript!) as the number of participants is limited to 80.  

3rd – 5th May 2023

EPO will participate at the Cancer Immunotherapy Meeting (CIMT) Meeting 2023 in Mainz, Germany

The annual CIMT event is Europe’s largest immunotherapy meeting and EPO will be presenting its very recent developments in immune oncology research at this meeting in May 2023 in Mainz, Germany. We will be happy to meet everyone at our posters, who is interested in our research and services in immune oncology, humanized mouse and PDX models for scientific exchange and discussions.

• Poster # 115: Human leukocyte antigen (HLA) matching of cancer patient-derived xenografts (PDX) models with immune cell-humanized mice
  
• Matching of human leukocyte antigen (HLA) profiles of patient-derived xenografts (PDX) with human immune cell populations that are used for humanization of mouse models is a prerequisite for testing immune checkpoint inhibitors and mimics closer the clinical situation.
• HLA profiles of 291 established PDX models from 18 different tumor entities were analyzed and matched to known peripheral blood mononuclear cell (PBMC) donors according to the donor-recipient HLA matching criteria recommended by the Blood and Marrow Transplant Clinical Trials Network.
• HLA-matched PDX and immune cells were engaged in an in vivo model and showed a response to checkpoint inhibition.

  Download this poster (5th May 2023)


---

• Poster # 273: Humanized mouse models for the preclinical evaluation of novel cancer immunotherapy options
  
• The preclinical evaluation of many novel immune therapies requires the use mouse models with a functional human immune system. To this end, we have established human tumor-immune-cell models of different entities using CDX or PDX in combination with different donor derived immune cell subsets as effector cells.
• Our human tumor-immune-cell models allow preclinical, translational studies on tumor immune biology as well as evaluation of new therapies, drug combinations and biomarker identification and validation.

  Download this poster (5th May 2023)

14th – 19th April 2023

EPO will be present at the AACR Annual Meeting 2023 in Orlando, FL

EPO will be presenting its newest achievements in research and development at the AACR Annual Meeting in Orlando, Florida, held from 14th to 19th of April 2023. We will present posters and will be happy to meet you at the posters for lively discussions

• Poster # 5204: Preclinical models for translational immuno-oncology research: rare patient-derived xenografts on humanized mic
  
• Fully humanized mouse models for immuno-onoclogy research by co-transplantation of PDX and human hematopetic stem cells (HSC) or immune cells from whole blood (PBMCs, T, or NK cells).
• Several rare and difficult to establish tumor models have been investigated in humanized HSC mice.
• The models have been experimentally validated in preclinical studies with checkpoint inhibitors, novel bispeci¬c immune cell engagers (BITE) or cell therapy options such as CAR-T cells.

  Download this poster


---

• Poster # 4674: Patient-derived xenograft and PDX-derived cell line models from glioblastoma for drug development and identification of molecular signatures
  
• Establishment of 39 PDX glioma models on immunodeficient mice, fiveteen out of these by orthotopic (i.cer.) transplantation.
• Subcutaneously transplanted PDX models show individual growth and chemosensivity profiles and matching orthotopic PDX models have a reduced sensivity towards most tested drugs, possibly due to the blood-brain barrier and altered microenvironment.
• PDX-derived GBM cell cultures for in vitro pre-testing are free of murine cells, show individual morphology and similar response patterns towards selected drugs as their matching in vivo counterparts

  Download this poster

---

• Poster # 44: An in vivo platform of pre-characterized renal cell carcinoma (RCC) patient-derived xenograft models allows the preclinical evaluation of patient-tailored intervention strategies
  
• A comprehensive panel of subcutaneous RCC PDX models with well-conserved molecular and pathological features.
• Drug screening towards four SoC drugs, targeting the VEGF and PI3K/mTOR pathway revealed individual and heterogeneous response profiles in these model which resembles the clinical situation.
• Intra-tumor heterogeneity can be assessed via PDX models from multi-tumor regions from one patient.

  Download this poster

15^th - 17^th of February 2023

EPO is attending the International AEK Cancer Congress in Kassel, Germany

EPO will attend the 21st International AEK Cancer Congress in Kassel, Germany, which is funded by the German Cancer Society. This meeting covers different topics of current cancer research including cancer immunology, metastasis research, cancer biology and many more.

EPO will participate actively at this meeting and presenting a talk on “Humanized mouse models for preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers” on 16^th of February and a poster on our newest achievements regarding“Human leukocyte antigen (HLA) matching of cancer patient-derived xenografts (PDX) models for preclinical immune-oncology studies”.

This is a good opportunity to meet us at the AEK Cancer Congress and to discuss new developments and projects.

13th – 16th of November 2022

35. Deutscher Krebskongress Berlin (35th German Cancer Congress Berlin)

EPO scientists presented new models for preclinical translational cancer research in two lectures at the plenary session "Translational Oncology: Innovative Tumor Models - Translation into the Clinic or Remaining in the Laboratory?" Our colleague Dr. Simone Rhein presented new "Humanized tumor models for immuno-oncology research" and Dr. Jens Hoffmann reported on "New approaches for the use of patient-derived xenografts in translational oncology".

In the poster sessions of the congress, further EPO researchers presented the development of patient-derived xenograft (PDX) models from high-risk childhood cancers for preclinical evaluation of novel therapeutics, presented new data on HLA-typing of PDX models for improved immune oncology applications and on thorough characterization of newly established PDX models derived from peritoneal metastases of colorectal cancer (all published in the special issue of Oncol Res Treatment, Vol. 45, Suppl. 3, 2022).

26^th - 28^th October 2022

See and meet EPO at the 34th EORTC-NCI-AACR (ENA) Meeting in Barcelona, Spain:

EPO is happy to announce its presence at the 34th ENA-Meeting on molecular targets and cancer therapeutics from 26. - 28. October at the “Centre de Conventions International” in Barcelona, Spain. You can meet EPO’s experts at the EPO-booth during the meeting to discuss our service portfolio, which is ready to aid your projects or specific studies. We will be happy to talk about your needs, answer your questions and discuss potential collaborations.

In addition, EPO is presenting the following scientific posters at the meeting: 

• Humanized mouse models for preclinical evaluation of novel immune therapies, checkpoint inhibitors and immune cell engagers (Poster #32)
• Establishment and characterization of a preclinical platform of subcutaneous renal cell carcinoma (RCC) patient-derived xenograft models to
  evaluate novel treatment strategies (Poster #33)
• New patient derived lymphoma xenograft (PDX) panel for drug development, immune-oncology and translational research (Poster #115)

Take your chance and meet us at our posters during the meeting to gain more insights on our expertise and capabilities as a contract research organization with more than 25 years of experience.

26^th August 2022

Meet EPO at the Immunotherapy Of Cancer (ITOC) Meeting from the 22nd to the 24th of September in Munich, Germany:

EPO will be present at this important European meeting of translational research in immuno-oncology. The meeting will be the perfect opportunity to meet our experts for cancer immuno therapy as well as humanized mouse models and to discuss your projects in the prospect of potential collaborations.

During the meeting, EPO and TACONIC are happy to invite interested researchers to their first joint dinner-symposium at the 22^nd of September with focus on Humanized Immune System Mice in Oncology Research at the Hotel zum Erdinger Weissbräu in Munich. This symposium offers great opportunities for scientific exchange and discussions and the detailed program can be found here. Please register as soon as possible by writing an email to Katja Bolle (Turn on Javascript!) as the number of participants is limited to 50.

4^th April 2022

EPO is presenting at the AACR Annual Meeting 2022 in New Orleans

Get up-to-date on the latest discoveries in cancer research and meet us at the AACR Annual Meeting held from the 8th to the 13th of April in New Orleans.
Please use the opportunity to view our posters which have been accepted by the AACR for presentation:

Poster: Humanized mouse models for preclinical evaluation of novel immune cell therapies, checkpoint inhibitors, and immune cell engangers (PDF)
Poster: Breaking the crosstalk of the Cellular Tumorigenic Network in NSCLC by a highly effective drug combination (PDF)